HomeHeadlinesSanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesAPRIL 24, 2026 AT 10:10 AMSanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesByNewsquawk StaffImportanceLevel 1#FRANCE#EUROPE#SANOFI#SAN.FP#BANCO SANTANDER SA#EQUITIES#EU SESSION#PHARMACEUTICALS#DIVERSIFIED BANKS#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#CAC 40 INDEX#SANOFI SA#CACExternal
APRIL 24, 2026 AT 10:10 AMSanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesByNewsquawk StaffImportanceLevel 1#FRANCE#EUROPE#SANOFI#SAN.FP#BANCO SANTANDER SA#EQUITIES#EU SESSION#PHARMACEUTICALS#DIVERSIFIED BANKS#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#CAC 40 INDEX#SANOFI SA#CACExternal
